Related Experiment Video
Updated: Jul 4, 2025

09:21
Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors
Published on: January 29, 2019
36.4K
Microfluidic AAV Purity Characterization: New Insights into Serotype and Sample Treatment Variability
Adriana Coll De Peña1, James D White2, Dipti R Mehta2
1Center for Biomedical Engineering, School of Engineering, Brown University, Providence, Rhode Island 02912, United States.
ACS Omega
|January 29, 2024
Summary
A new microfluidic electrophoresis method rapidly assesses adeno-associated virus (AAV) full capsids, crucial for gene therapy manufacturing. This high-throughput technique analyzes multiple AAV serotypes efficiently, improving quality control for viral vector production.
Area of Science:
- Biotechnology
- Molecular Biology
- Analytical Chemistry
Background:
- Adeno-associated virus (AAV) is a leading gene delivery platform due to low immunogenicity and high efficiency.
- Manufacturing high-quality AAV requires rapid analytical techniques, especially for assessing full capsids.
- Current methods for full capsid assessment are often slow and lack high-throughput capabilities across diverse AAV serotypes.
Purpose of the Study:
- To develop and validate a rapid, high-throughput analytical technique for assessing adeno-associated virus (AAV) full capsids.
- To establish a method compatible with multiple AAV serotypes without extensive optimization.
- To provide a robust tool for quality control in AAV manufacturing.
Main Methods:
- Utilized microfluidic electrophoresis for rapid assessment of AAV full capsids.
- Developed a mathematical formulation combining capsid protein and single-stranded DNA (ssDNA) profiles using a reference standard.
- Evaluated the use of a single serotype (AAV8) as a reference standard for other serotypes within a specific melting temperature range.
Main Results:
- The microfluidic electrophoresis method demonstrated compatibility with AAV1, AAV2, AAV6, AAV8, and AAV9, with some constraints for AAV5.
- The assay achieved characterization of samples with an accuracy of ±6.1%.
- The analytical turnaround time was less than 5 minutes per sample, requiring only 10 μL at a concentration of 2.5 × 10^12 VG/mL.
Conclusions:
- Microfluidic electrophoresis offers a rapid and high-throughput solution for assessing AAV full capsids.
- This technique supports the quality control of AAV manufacturing across various serotypes.
- The developed method addresses a critical bottleneck in viral vector production for gene therapy.

